| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 0.86/mg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Nafamostat mesylate (NM), a synthetic serine protease inhibitor first placed on the market by Japan Tobacco in 1986, has been approved to treat inflammatory-related diseases, such as pancreatitis.
Namorestat mesylate is a synthetic protease inhibitor, which can prolong the coagulation time, inhibit platelet agglutination and complement hemolysis by inhibiting the coagulation and fibrinolysis system, kallikrein · kinin system and complement system.
Prevent blood clotting by perfusion during cardiopulmonary bypass (hemodialysis and plasma storage).
Treatment of acute pancreatitis, acute worsening chronic pancreatitis, postoperative acute pancreatitis, acute pancreatitis after pancreatic angiography and acute traumatic pancreatitis.Treatment of disseminated intravascular coagulation (DIC).
| Item | Test Standard | Testing Result | |
| Assay | 98% | Complies | |
| Apperence | White Powder | Complies | |
| Particle Size | 100% pass 80 mesh | Complies | |
| Oder | Characteristic | Complies | |
| Taste | Characteristic | Complies | |
| Loss on Drying | ≤5.0% | 2.20% | |
| Residue on Ignition | ≤0.1% | 0.05% | |
| Residual | ≤0.1% | Complies | |
| Residual Ethanol | ≤0.5% | Complies | |
| Heave Mentals | ≤10ppm | Complies | |
| Na | ≤0.1% | <0.1% | |
| Pb | ≤3 ppm | Complies | |
| Total Plate | <1000CFU/g | Complies | |
| Yeast & Mold | <100 CFU /g | Complies | |
| E. Coli | Negative | Complies | |
| Salmonella | Negative | Complies | |
){kind=link}